Found: 11
Select item for more details and to access through your institution.
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 5, p. 1570, doi. 10.1007/s10637-020-00910-9
- By:
- Publication type:
- Article
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11153-1
- By:
- Publication type:
- Article
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.
- Published in:
- Frontiers in Oncology, 2020, v. 11, p. N.PAG, doi. 10.3389/fonc.2020.578756
- By:
- Publication type:
- Article
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
- Published in:
- International Journal of Molecular Sciences, 2017, v. 18, n. 5, p. 995, doi. 10.3390/ijms18050995
- By:
- Publication type:
- Article
Assessment of Diet-induced Obese Rats as an Obesity Model by Comparative Functional Genomics.
- Published in:
- Obesity (19307381), 2008, v. 16, n. 4, p. 811, doi. 10.1038/oby.2007.116
- By:
- Publication type:
- Article
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
- Published in:
- Drug Design, Development & Therapy, 2015, v. 9, p. 4479, doi. 10.2147/DDDT.S86621
- By:
- Publication type:
- Article
Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
- Published in:
- PLoS ONE, 2020, v. 15, n. 3, p. 1, doi. 10.1371/journal.pone.0222259
- By:
- Publication type:
- Article
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Promoter recognition and discrimination by Eσ<sup>S</sup> RNA polymerase.
- Published in:
- Molecular Microbiology, 2001, v. 42, n. 4, p. 939, doi. 10.1046/j.1365-2958.2001.02703.x
- By:
- Publication type:
- Article
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article